Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study.
Michael D TarantinoBrandon M HardestyAra MetjianThomas L OrtelJie ChenKayode BadejoAlice MaAdam CukerAnita RajasekharKenneth D FriedmanMaissaa JanbainPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2023)
In this real-world study of rpFVIII for AHA, no new safety signals were identified compared with previous clinical trial findings. Eighty percent of bleeds resolved with rpFVIII treatment.